EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Consensus on the Clinical Use of Pregabalin in Peripheral Neuropathic Pain

Hui Lu iD, Yuefeng Rao iD, Jian Wang, Wan Shuanglin, Du Dongping, Ma Ke, Zhiying Feng iD, Suming Tian, Weidong Qiu, Xu Jing, Zhongwei Zhao, Zhenhua Zeng und 11 weitere

CNS Neuroscience & Therapeutics · 2026-06 · 32 (6)

DOI: 10.1002/cns.70866 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 17.06.2026. Verfasst von Hui Lu und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Pregabalin, Neuralgia, Analgesics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Peripheral neuropathic pain (pNP) is a prevalent and complex clinical condition that presents significant therapeutic challenges, with pharmacological options demonstrating variable efficacy and safety.

Objective

To establish expert consensus recommendations on the clinical use of pregabalin in the management of diverse pNP conditions.

Methods

A multidisciplinary panel of Chinese experts from orthopedics, pain management, neurology, oncology, dermatology, and pharmacy conducted a comprehensive literature review and synthesized clinical evidence to formulate consensus‐based recommendations.

Results

Pregabalin, a second‐generation calcium channel regulator, demonstrated broad efficacy across multiple pNP conditions, including postherpetic neuralgia (PHN), diabetic peripheral neuropathy (DPN), neuropathic cancer pain (NCP), postoperative and post‐traumatic neuralgia, and trigeminal neuralgia (TN). In PHN, pregabalin significantly reduced pain intensity and improved sleep quality. In DPN, it provided consistent analgesia with improved pain scores and good tolerability. In NCP, pregabalin effectively alleviated pain, showed no significant drug–drug interactions, and was safely co‐administered with chemotherapy. It was also effective in postoperative and post‐traumatic neuralgia, although caution is warranted in cases of traumatic neuroma. In TN, pregabalin exhibited favorable low‐dose efficacy, particularly in elderly patients, with minimal adverse effects. However, cautious use is advised in patients with nerve compression syndromes, such as carpal tunnel syndrome, and in individuals with a history of substance abuse.

Conclusions

This consensus highlights pregabalin as an effective and generally well‐tolerated therapeutic option for a broad range of pNP conditions. These recommendations provide clinically relevant guidance for optimizing pregabalin use, particularly within the Chinese healthcare context.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PregabalinNeuralgiaAnalgesicsHumans

Stichwörter der Autor:innen

adverse reactionscancer paindiabetic peripheral neuralgiaperipheral neuropathic painpostherpetic neuralgiapostoperative chronic neuralgiapost‐traumatic neuralgiapregabalin

Substanzen

PregabalinAnalgesics

Autor:innen und Institutionen

  • Department of Orthopedics, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
  • Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou, Zhejiang, China.
  • Department of Wound Healing, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Department of Orthopedics, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, China.
  • Department of Pain Management, Shanghai Sixth People's Hospital, Shanghai, China.
  • Department of Pain Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.

ORCID-Profile: Hui Lu, Yuefeng Rao, Zhiying Feng, Benyan Luo, Xianfeng Zhang, Qingwei Zhao

Zitieren

APA

Lu, H., Rao, Y., Wang, J., Shuanglin, W., Dongping, D., Ke, M., Feng, Z., Tian, S., Qiu, W., Jing, X., Zhao, Z., Zeng, Z., Luo, B., Wang, C., Zhao, H., Liu, K., Lin, L., Zhang, X., Liyan, G., …, & Hu, Y. (2026). Consensus on the Clinical Use of Pregabalin in Peripheral Neuropathic Pain. CNS Neuroscience & Therapeutics, 32(6). https://doi.org/10.1002/cns.70866

Vancouver

Lu H, Rao Y, Wang J, Shuanglin W, Dongping D, Ke M, et al. Consensus on the Clinical Use of Pregabalin in Peripheral Neuropathic Pain. CNS Neuroscience & Therapeutics. 2026;32(6). doi:10.1002/cns.70866

BibTeX
@article{Lu2026,
  author = {Lu, Hui and Rao, Yuefeng and Wang, Jian and Shuanglin, Wan and Dongping, Du and Ke, Ma and Feng, Zhiying and Tian, Suming and Qiu, Weidong and Jing, Xu and Zhao, Zhongwei and Zeng, Zhenhua and Luo, Benyan and Wang, Changqing and Zhao, Hui and Liu, Kaiming and Lin, Li and Zhang, Xianfeng and Liyan, Gong and Lu, Haiqi and Liu, Yan and Zhao, Qingwei and Hu, Yihe},
  title = {Consensus on the Clinical Use of Pregabalin in Peripheral Neuropathic Pain},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2026},
  volume = {32},
  number = {6},
  doi = {10.1002/cns.70866}
}
Kostenlos starten →